Article Text

PDF
THU0295 Clinical features of takayasu's arteritis from an inception cohort: early disease is characterized by “systemic inflammation”
  1. F Alibaz-Oner,
  2. on behalf of Turkish Takayasu Arteritis Study Group
  1. Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

Abstract

Background There is only retrospective and very limited data for the long term prognosis of Takayasu's Arteritis (TAK), a rare large-vessel vasculitis. In this study, we aimed to present the preliminary results of a Takayasu Inception Cohort settled for long term, prospective follow-up of only newly-diagnosed patients with TAK.

Methods Patients fullfilling the American College of Rheumatology 1990 criteria for TAK and diagnosed in the last 12 months were included to the study. Patients' data were recorded in an electronic database of an international “Takayasu's Arteritis Registry” requiring baseline and at least annual visits. Data is compared with an historical Turkish cohort previously published (Bıçakçıgil, et al, 2009).

Results The study included 128 patients (age: 38.9±13.1 years, F/M: 112/16) with TAK from 15 tertiary Rheumatology centers in Turkey. The mean symptom duration of patients was 5.2 years at diagnosis. According to the angiographic classification, 59.2% of the study group had type I and only 17.2% had type V disease. When we compared our results to our retrospective cohort (previously published by Turkish Takayasu Arteritis Study Group), constitutional symptoms (72.2% vs 66%) and limb claudication (62.3% vs 48%) were observed to be more frequent, whereas pulselessness (35.6% vs 88%) was less in the inception cohort.(Table 1) Carotidynia was present only in the inception cohort. Similarly, mucocutaneous symptoms also seem to be a feature of newly-diagnosed disease (26.4% vs 8.8%). Regarding comorbidities at diagnosis, the rate of dyslipidemia was 22%, diabetes mellitus 6%, smoking 28.5% and obesity (BMI>30) 15.8% among TAK patients. All patients were given oral corticosteroid (CS) therapy (0.5–1 mg/kg) at diagnosis, 10 patients (7.8%) also having CS pulses. In addition to CSs, 55 patients (43%) were given methotrexate, 14 patients (11%) azathioprine and 5 (4%) cyclophosphomide at disease-onset.

Table 1.

Clinical characteristics of Inception and Retrospective Cohorts from Turkey

Conclusions Our results suggest that, in an inception cohort, signs and symptoms of “systemic inflammation” is more prominent in newly-diagnosed TAK patients, whereas vascular extent and damage accumulates during the disease course. The long term follow-up of our inception cohort will better show the actual course and predictors of prognosis in TAK.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.